Clinical Trials Sponsored by Immuno-US

Total 1647 results

National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals

HIV Infections

United States
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
Bionor Immuno AS

Completed

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

HIV I Infection

Germany, United States, Spain, United Kingdom, Italy
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Immuno-US

Completed

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

HIV Infections

United States
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
Immune Design

Terminated

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Melanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Immune Pharmaceuticals

Unknown

Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

Israel
Immune Control

Unknown

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Multiple Myeloma

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Immune Design

Completed

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States
Immune Pharmaceuticals

Completed

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

Pemphigoid, Bullous

United States, Israel
Immune Design

Completed

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Melanoma | Sarcoma | Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Teligene US

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Solid Tumor
Teligene US

Recruiting

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Teligene US

Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

United States
US Bionics

Completed

Phoenix Exoskeleton for SCI Users

SCI - Spinal Cord Injury

Hong Kong, United States
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
University of Miami
Immuno Laboratories

Completed

IgG-mediated Food Test for Weight Loss

Overweight and Obesity

United States
Smart Immune SAS

Recruiting

Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors (SMART101-HV1)

Healthy Volunteers

France
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Repertoire Immune Medicines

Terminated

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Melanoma | Cervical Cancer | Head and Neck Squamous Cell Carcinoma

United States
Repertoire Immune Medicines

Terminated

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Melanoma | Head and Neck Cancer | HPV-Related Malignancy | Melanoma (Skin) | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Lung Cancer, Nonsmall Cell

United States
AC Immune SA

Withdrawn

A Study of ACI-24 in Adults With Down Syndrome

Down Syndrome
IMMUNOe Research Centers

Unknown

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Covid19 | Post-Viral Fatigue Syndrome | Post-Viral Disorder (Disorder)

United States
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Us Helping Us, People Into Living, Inc.

Not yet recruiting

Predictors of Health Service Utilizations Among Key Population in Washington DC

HIV | Health Behavior | Pre-exposure Prophylaxis
Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Us Helping Us, People Into Living, Inc.

Recruiting

SNS and PrEP Initiation and Adherence in Black SMM

HIV

United States
Immuno Cure 3 Limited
The University of Hong Kong

Active, not recruiting

Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)

COVID-19

Hong Kong
Smart Immune SAS

Recruiting

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Hematological Malignancies

France
Immune-Onc Therapeutics

Recruiting

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Smart Immune SAS

Recruiting

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

Hematological Malignancies

United States
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
Tunisian Association for Immuno-oncology Research

Not yet recruiting

Biomarkers in Patients With Metastatic Breast Cancer (BIOPEACE)

Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
Imunon

Terminated

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) (ABLATE)

Colon Cancer Liver Metastasis

United States
US Oncology Research

Recruiting

MYLUNG Consortium Part 3: Observational Study (MYLUNG)

Carcinoma, Non-Small-Cell Lung

United States
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Curium US LLC

Active, not recruiting

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Metastasis From Malignant Tumor of Prostate

United States, France, Spain, Italy
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors: IMA202-101 (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Optinose US Inc.

Terminated

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

Covid19

Mexico
Optinose US Inc.

Completed

12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Nasal Polyps

United States

3

Subscribe